Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms

Pathophysiology of thrombosis in myeloproliferative neoplasms.

p53 as a target in myeloproliferative neoplasms

The Philadelphia chromosome negative myeloproliferative neoplasms (MPN) originate at the level of the pluripotent hematopoietic stem cell (HSC). JAK2V617F is present in virtually all patients with polycythemia vera (PV) as well as 50-60% of patients with primary myelofibrosis (PMF) and essential thrombocythemia (ET) [1]. Recently, Nakatake and coworkers demonstrated that JAK2V617F alters p53 re...

Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.

To update oncologists on pathogenesis, contemporary diagnosis, risk stratification, and treatment strategies in BCR-ABL1-negative myeloproliferative neoplasms, including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Recent literature was reviewed and interpreted in the context of the authors' own experience and expertise. Pathogenetic mechanisms in PV,...

Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.

The genetic landscape of classical myeloproliferative neoplasm (MPN) is in large part elucidated. The MPN-restricted driver mutations, including those in JAK2, calreticulin (CALR), and myeloproliferative leukemia virus (MPL), abnormally activate the cytokine receptor/JAK2 pathway and their downstream effectors, more particularly the STATs. The most frequent mutation, JAK2V617F, activates the 3 ...

Myeloproliferative Neoplasms: A Contemporary Review.

Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) constitute the BCR-ABL1-negative myeloproliferative neoplasms and are characterized by mutually exclusive Janus kinase 2 (JAK2), calreticulin (CALR), and myeloproliferative leukemia virus oncogene (MPL) mutations; respective frequencies of these mutations are approximately 95%, 0%, and 0% in PV, 60%, 20%, an...